Specific targeting of VEGF+ TAM subsets responsible for immunosuppressive angiogenesis, while sparing the T cell attractant FOLR2+ and peri-HEV TAMs, may improve the TME and sensitize the tumor to ICB treatment (149). Here, FOLR2 is linked to neoplasm.